|
|
|
| |
Polyclonal Antibody to human EBI3 |
|
|
| |
|
|
| |
|
| Catalog No: |
IMG-6100A |
| Contents: |
100 ug in 200 ul PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic. |
| Isotype: |
Rabbit IgG |
| Purification: |
Protein G Chromatography |
| Species: |
Chimpanzee, Human |
| Predicted React: |
New World monkey |
| Host: |
Rabbit |
| Application: |
Western blot analysis: 2-5 ug/ml |
| Storage: |
Store at 4°C, stable for 6 months. For long term storage, aliquot and store at -20°C. |
|
 |
|
|
|
|
|
|
Background
EBI3 is a 229 amino acid cytokine belonging to the type I cytokine receptor family (type 3 subfamily) with a signal peptide, 2 potential N-linked glycosylation sites, an LSDWS motif, 2 fibronectin type-III domains. It is usually induced due to infection of B lymphocytes by Epstein-Barr virus and due to expression of an EBV encoded latent membrane protein. EBI3 is a subunit of two heterodimeric cytokines interleukin-27 (IL27) and IL35. It is a secreted glycoprotein associated with calnexin and is a heterodimer with an alpha and a beta subunit. It is also known to interact with SQSTM1 and is responsible for the rapid clonal expansion of naive but not memory CD4 (+) T-cells. It strongly synergizes with IL-12 and trigger IFN-gamma production of naive CD4 (+) T-cells. It mediates its biologic effects through the cytokine receptor WSX-1/TCCR. It triggers signaling in T cells, B cells, and myeloid cells and along with p35 it acts as an important immunomodulator. It is usually expressed in various hemopoietic tissues and cell lines. |
Antigen
A portion of amino acids 120-170 of human EBI3 was used as the immunogen. |
Application Notes
The amino acid sequence used as immunogen is 100% homologous in human (isoform CRA_a and CRA_b), chimpanzee and 94% homologous in monkey.
EBI3 is routinely seen in western blot at approximately 35 kD. View additional EBI3 antibodies |
Genebank Info (Protein)
NP_005746 |
| |
|
Western blot analysis of EBI3 in Jurkat cell lysate in the 1) absence and 2) presence of immunizing peptide at 2 ug/ml and 3) recombinant human IL-35 protein at 5 ug/ml using EBI3 antibody. |
|
|
|
|
|
| - |
 |
|
Reference
1. Collison, LW. et al. Nature. 450:566-569 (2007).
2. Pflanz, S. et al. J. Immun. 172:2225-2231 (2004).
3. Pflanz, S. et al. Immunity. 16:779-790 (2002).
|
|
|
|
Research purposes only.
Not for diagnostic or in vivo use. This product is guaranteed to perform as indicated on the datasheet for one year from the date of purchase.
|
|
|
|
|
